New Delhi, Feb. 19 -- In the face of looming revenue decline from blood cancer medication Revlimid, Indian pharma companies Natco Pharma and Dr. Reddy's Laboratories are shifting their focus to a promising new frontier: a weight loss drug modelled after Ozempic. This strategic pivot aims to stabilise their growth and set them on a path toward recovery in an ever-evolving market.

Since last week, Natco Pharma's shares have plunged over 30%, after the company posted weak Q3 earnings, on account of the absence of sales of Revlimid during the quarter. The company reported a sharp 39% year-on-year decline in its revenue (excluding other income) to Rs.464 crore in Q3FY25. While the company said that this was a one-off event due to its volume q...